Aix, S. P., Ciuleanu, T. E., Navarro, A., Cousin, S., Bonanno, L., Smit, E. F., Chiappori, A., Olmedo, M. E., Horvath, I., Grohé, C., Farago, A. F., López-Vilariño, J. A., Cullell-Young, M., Nieto, A., Vasco, N., Gómez, J., Kahatt, C., Zeaiter, A., Carcereny, E., Roubec, J., Syrigos, K., Lo, G., Barneto, I., Pope, A., Sánchez, A., Kattan, J., Zarogoulidis, K., Waller, C. F., Bischoff, H., Juan-Vidal, O., Reinmuth, N., Dómine, M., & Paz-Ares, L. (2023). combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial. Lancet, 11(1), 74–86. http://access.bl.uk/ark:/81055/vdc_100173090117.0x000011